dolutegravir rilpivirine
Selected indexed studies
- Dolutegravir-rilpivirine coformulation. (Curr Opin HIV AIDS, 2018) [PMID:29553948]
- Dolutegravir/Rilpivirine: A Review in HIV-1 Infection. (Drugs, 2018) [PMID:30406902]
- Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection. (Ann Pharmacother, 2019) [PMID:30758229]
_Worker-drafted node — pending editorial review._
Connections
dolutegravir rilpivirine is a side effect of
Sources
- Dolutegravir-rilpivirine coformulation. (2018) pubmed
- Dolutegravir/Rilpivirine: A Review in HIV-1 Infection. (2018) pubmed
- Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection. (2019) pubmed
- Dolutegravir/rilpivirine for the treatment of HIV-1 infection. (2018) pubmed
- Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. (2018) pubmed
- Dolutegravir-rilpivirine for virological suppression. (2019) pubmed
- Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis. (2021) pubmed
- New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy. (2018) pubmed
- PMID:30645064 (2018) pubmed
- Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. (2021) pubmed